Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | PPID | Q08752 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806762 | 0.90 | EPHX2 (0.56) | PPIDLMNAL3MBTL1EPHX2CYP3A4 | |
| SCHEMBL18124427 | 0.90 | HDAC1 (0.51) | HDAC1PLAUPPIDLMNAEPHX2 | |
| SCHEMBL5803249 | 0.89 | NPC1 (0.62) | LMNAEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL18124428 | 0.88 | TSHR (0.51) | HDAC1EPHX2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL28969034 | 0.87 | NPC1 (0.63) | LMNAEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL28969065 | 0.87 | NPC1 (0.63) | LMNAEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL8773507 | 0.87 | NPC1 (0.63) | LMNAEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL27621693 | 0.87 | NPC1 (0.63) | LMNAEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL29106946 | 0.87 | NPC1 (0.63) | LMNAEPHX2CYP3A4ALDH1A1 | |
| SCHEMBL28105060 | 0.87 | NPC1 (0.63) | LMNAEPHX2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9817156-B2 | Polarizing plate protective film, polarizing plate and display device | FUJIFILM CORPORATION (JP) | 2017-11-14 | — | — | US | disclosed |
| CN-104302290-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-01-21 | — | — | CN | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| CN-100537523-C | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-100516034-C | Aspartyl protease inhibitors | VERTEX PHARMA CO LTD (US) | 2009-07-22 | — | — | CN | disclosed |
| CN-101245058-A | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2008-08-20 | — | — | CN | disclosed |
| CN-1898199-A | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1361765-A | Aspartyl protease inhibitors | VERTEX PHARMA (US) | 2002-07-31 | — | — | CN | disclosed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0804428-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0801083-A2 | Improved functionalized resin for chemical synthesis | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | HDAC1 70/4885PLAU 2395/4885PPID 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.